MindWalk Holdings (HYFT) Cost of Revenue (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Cost of Revenue of $1.2 billion for Q2 2026, up 50185807.77% year-over-year from N/an in Q2 2025, and up 96817640414.14% quarter-over-quarter from $1.22 in Q1 2026.
MindWalk Holdings (HYFT) Cost of Revenue (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Cost of Revenue for 7 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Cost of Revenue rose 50185807.77% year-over-year to $1.2 billion; the TTM figure through Apr 2026 stood at $1.2 billion (up 43570.99% YoY), while the FY2026 annual figure was $4.7 million, up 33.07% from the prior year.
- Cost of Revenue rose to $1.2 billion in Q2 2026 per HYFT's latest filing, from $1.22 in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.2 billion in Q2 2026 and bottomed at -$2.2 million in Q2 2024.
- Historically, Cost of Revenue has averaged $66.6 million across 5 years, with a median of $1.4 million in 2025.
- Annual changes were most pronounced in 2024 — Cost of Revenue sank 228.11% — and 2026, when it surged 50185807.77%.
- MindWalk Holdings' Cost of Revenue stood at $1.8 million in 2022, then tumbled by 99.87% to $2357.0 in 2023, then surged by 40599.44% to $959298.2 in 2024, then advanced by 9.86% to $1.1 million in 2025, then surged by 112033.18% to $1.2 billion in 2026.
- Business Quant data shows HYFT's Cost of Revenue at $1.2 billion in Q2 2026, $1.22 in Q1 2026, and $1.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.18 Bn |
| Apr 30, 2026 | 1.18 Bn |
| Jan 31, 2026 | 1.22 |
| Jan 31, 2026 | 1.22 |
| Oct 31, 2025 | 1.05 Mn |
| Oct 31, 2025 | 1.05 Mn |
| Jul 31, 2025 | 1.19 Mn |
| Jul 31, 2025 | 1.19 Mn |
| Apr 30, 2025 | 2,354.84 |
| Apr 30, 2025 | 2,354.84 |
| Jan 31, 2025 | 681,180.77 |
| Jan 31, 2025 | 681,180.77 |
| Oct 31, 2024 | 959,298.20 |
| Oct 31, 2024 | 959,298.20 |
| Jul 31, 2024 | 1.07 Mn |
| Jul 31, 2024 | 1.07 Mn |
| Apr 30, 2024 | -2.16 Mn |
| Apr 30, 2024 | -2.16 Mn |
| Jan 31, 2024 | 2.24 Mn |
| Jan 31, 2024 | 2.24 Mn |